Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor

To our knowledge, no structural study to date has characterized, in an intact receptor, the coupling of conformational change in extracellular domains through a single-pass transmembrane domain to conformational change in cytoplasmic domains. Here we examine such coupling, and its unexpected complexity, using nearly full-length epidermal growth factor receptor (EGFR) and negative-stain EM. The liganded, dimeric EGFR ectodomain can couple both to putatively active, asymmetrically associated kinase dimers and to putatively inactive, symmetrically associated kinase dimers and monomers. Inhibitors that stabilize the active or inactive conformation of the kinase active site, as well as mutations in the kinase dimer interface and a juxtamembrane phosphorylation site, shift the equilibrium among the three kinase association states. This coupling of one conformation of an activated receptor ectodomain to multiple kinase-domain arrangements reveals previously unanticipated complexity in transmembrane signaling and facilitates regulation of receptor function in the juxtamembrane and cytoplasmic environments.

[1]  Shigeyuki Yokoyama,et al.  Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor , 2010, Molecular and Cellular Biology.

[2]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[3]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[4]  F. Sicheri.  Faculty Opinions recommendation of Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. , 2007 .

[5]  R. Radhakrishnan,et al.  ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation , 2010, Proceedings of the National Academy of Sciences.

[6]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[7]  A Leith,et al.  SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. , 1996, Journal of structural biology.

[8]  K. Takishima,et al.  Role of threonine residues in regulation of the epidermal growth factor receptor by protein kinase C and mitogen-activated protein kinase. , 1993, The Journal of biological chemistry.

[9]  G. Carpenter,et al.  125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts , 1976, The Journal of cell biology.

[10]  Hyun-soo Cho,et al.  Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.

[11]  T. Walz,et al.  Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs. , 2008, Biochemistry.

[12]  Edouard C. Nice,et al.  Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.

[13]  Matthew Meyerson,et al.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.

[14]  Jonathan A. Cooper,et al.  Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane , 1984, Nature.

[15]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[16]  G. Heisermann,et al.  Epidermal growth factor receptor threonine and serine residues phosphorylated in vivo. , 1988, The Journal of biological chemistry.

[17]  Xuejun Jiang,et al.  Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. , 2006, Molecular cell.

[18]  G. Carpenter,et al.  Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation , 2007, Proceedings of the National Academy of Sciences.

[19]  M. Eck,et al.  Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. , 2010, Biochimica et biophysica acta.

[20]  W Chiu,et al.  EMAN: semiautomated software for high-resolution single-particle reconstructions. , 1999, Journal of structural biology.

[21]  A. Ullrich,et al.  Mig-6 Is a Negative Regulator of the Epidermal Growth Factor Receptor Signal , 2001, Biological chemistry.

[22]  A. Ullrich,et al.  Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing , 1987, Cell.

[23]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.

[24]  A. Pozzi,et al.  The juxtamembrane region of the EGF receptor functions as an activation domain. , 2009, Molecular cell.

[25]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[26]  A. Sorokin.  Activation of the EGF receptor by insertional mutations in its juxtamembrane regions. , 1995, Oncogene.

[27]  H. Wiley,et al.  Mutational removal of the Thr669 and Ser671 phosphorylation sites alters substrate specificity and ligand-induced internalization of the epidermal growth factor receptor. , 1990, The Journal of biological chemistry.

[28]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[29]  John Kuriyan,et al.  Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.